샘플 요청 목록

 카트 문의
시장보고서
상품코드
1536090

세계 예방접종 시장

Preventable Vaccines
발행일: | 리서치사: 구분자 Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 391 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

예방접종 세계 시장은 2030년까지 929억 달러에 도달

2023년에 856억 달러로 추정되는 예방접종 세계 시장은 2023-2030년 분석 기간에 CAGR 1.2%로 성장하고 2030년에는 929억 달러에 이를 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 원시/약독화 백신은 CAGR 1.3%로 성장을 지속하고, 분석 기간 종료 시 341억 달러에 도달할 것으로 예측됩니다. 불활성화 백신 분야의 성장률은 분석 기간 동안 CAGR 1.6%로 추정됩니다.

미국 시장은 233억 달러로 추정, 중국은 CAGR 2.1%로 성장 예측

미국의 예방접종 시장은 2023년 233억 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 167억 달러 규모에 이를 것으로 예측되며, 분석 기간 2023-2030년의 CAGR은 2.1%입니다. 기타 주목할만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 0.6%와 1.0%로 예측되고 있습니다. 유럽에서는 독일이 CAGR 약 0.7%로 성장할 것으로 예측됩니다.

세계의 예방접종 시장- 주요 동향과 촉진요인 정리

예방접종은 병원체를 인식하고 효과적으로 싸우도록 면역계를 자극함으로써 개인과 집단을 감염으로부터 보호하기 위해 설계된 세계 보건 위생 무기로서 필수적인 도구입니다. 이러한 생물학적 제형은 질병을 일으키는 미생물과 그 구성 요소 중 하나를 무해한 형태로 체내에 도입하여 실제 질병을 일으키지 않고 면역계가 반응하고 면역을 구축하도록 촉구합니다. 이 메커니즘은 실제 병원체에 노출되어도 면역계가 더 빠르고 효과적으로 반응 할 수있게 합니다. 홍역, 볼거리, 풍진, 디프테리아, 백일해 등의 예방 접종을 포함한 정기 접종 백신은 세계 공중 보건 정책의 핵심입니다. 예방 접종은 많은 생명을 위협하는 질병의 근절과 상당한 감소로 이어지고 있으며, 현재도 집단 발생과 전염병 예방에 중요한 전략이되고 있습니다.

백신의 개발과 개발에는 복잡한 조사와 일반 사용이 승인되기 전에 안전성과 유효성을 확인하기 위한 엄격한 시험이 필요합니다. 수년에 걸쳐, 백신 기술은 약독화 백신 및 불활성화 백신으로부터 보다 정교한 아단위 백신, 재조합 백신, 결합형 백신, mRNA 백신으로 진화해 왔습니다. mRNA 백신과 같은 새로운 기술은 COVID-19와 같은 신흥 감염에 대응하는 신속한 개발을 가능하게 합니다. 게다가, 새로운 병원체에 신속하게 적응할 수 있는 백신 플랫폼의 출현은 특히 팬데믹에의 대응에 있어서, 이 분야에 혁명을 가져왔습니다. 인간의 건강뿐만 아니라 백신은 수의학적으로 매우 중요하며 가축을 질병으로부터 보호하여 식량 안보와 농업 경제를 지원합니다.

예방접종 시장의 성장은 예방접종 프로그램에 대한 정부 및 민간 자금 증가, 예방접종의 중요성에 대한 의식 증가 등 백신 개발의 기술 진보와 같은 여러 요인에 의해 견인되고 있습니다. 기술 혁신은 보조제 및 전달 시스템의 개발을 통해 면역 반응을 개선하고 부작용을 줄임으로써 보다 효과적이고 안전한 백신의 개발로 이어지고 있습니다. 국제보건기구와 정부의 지원을 통한 정기예방접종 프로그램의 세계 확대는 특히 저개발지역 및 개발도상지역에서의 백신 수요를 증대시키고 있습니다. 또한, 소비자의 행동은 최근 몇 년동안 크게 변화하고 있으며, 예방 건강 관리 대책에 대한 선호도가 높아지고 있습니다. 이것은 COVID-19의 대 유행에 의해 감염증의 제압에서 백신 접종의 중요한 역할이 입증되었습니다는 것이 더욱 박차를 가했습니다. 시장 확대는 다양한 병원체에 대한 노출을 증가시키는 여행과 이주 증가에 의해 촉진되고, 그 결과 보다 광범위한 예방접종의 필요성이 증가하고 있습니다. 이 역동적인 시장은 기존의 감염과 신흥 감염의 과제에 대응하기 위해 새로운 백신 기술과 국제 보건 이니셔티브가 확대됨에 따라 앞으로도 계속 성장할 것으로 예상됩니다.

조사 대상 기업 예(주목의 86사)

  • AstraZeneca PLC
  • Bharat Biotech International Ltd.
  • Boehringer Ingelheim International GmbH
  • Daiichi Sankyo Co., Ltd.
  • Emergent BioSolutions, Inc.
  • GSK Plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novavax, Inc.
  • Pfizer, Inc.
  • Roche CustomBiotech
  • Sanofi SA
  • Serum Institute of India Pvt., Ltd.
  • Takeda Pharmaceutical Co., Ltd.;

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 기타 중동
  • 아프리카

제4장 경쟁

JHS 24.08.29

Global Preventable Vaccines Market to Reach US$92.9 Billion by 2030

The global market for Preventable Vaccines estimated at US$85.6 Billion in the year 2023, is expected to reach US$92.9 Billion by 2030, growing at a CAGR of 1.2% over the analysis period 2023-2030. Live / Attenuated Vaccines, one of the segments analyzed in the report, is expected to record a 1.3% CAGR and reach US$34.1 Billion by the end of the analysis period. Growth in the Inactivated Vaccines segment is estimated at 1.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$23.3 Billion While China is Forecast to Grow at 2.1% CAGR

The Preventable Vaccines market in the U.S. is estimated at US$23.3 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$16.7 Billion by the year 2030 trailing a CAGR of 2.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.6% and 1.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.7% CAGR.

Global Preventable Vaccines Market - Key Trends and Drivers Summarized

Preventable vaccines are essential tools in the global health arsenal, designed to protect individuals and populations from infectious diseases by stimulating the immune system to recognize and fight pathogens effectively. These biological preparations introduce a harmless form of a disease-causing microorganism or one of its components into the body, prompting the immune system to respond and build immunity without causing the actual disease. This mechanism enables the immune system to respond more rapidly and effectively should the individual ever be exposed to the real pathogen. The routine vaccine schedule, which includes immunizations against diseases such as measles, mumps, rubella, diphtheria, and pertussis, is a cornerstone of public health policy worldwide. Vaccination has led to the eradication or significant reduction of many life-threatening diseases and continues to be a critical strategy in preventing outbreaks and epidemics.

The development and distribution of vaccines involve complex research and rigorous testing to ensure safety and efficacy before they are approved for public use. Over the years, vaccine technology has evolved from live-attenuated and inactivated forms to more sophisticated subunit, recombinant, conjugate, and mRNA vaccines. Each type is tailored to fight different pathogens in the most effective way possible, with newer technologies, such as mRNA vaccines, offering rapid development in response to emerging infectious diseases like COVID-19. Furthermore, the advent of vaccine platforms that can be quickly adapted to new pathogens has revolutionized the field, particularly in response to pandemics. Besides human health, vaccines are also crucial in veterinary practices, protecting livestock from diseases and thereby supporting food security and agricultural economies.

The growth in the preventable vaccines market is driven by several factors, including technological advancements in vaccine development, an increase in government and private funding for immunization programs, and a heightened awareness of the importance of vaccinations. Technological innovations have led to more effective and safer vaccines, with developments in adjuvants and delivery systems improving the immune response and reducing side effects. The global expansion of routine immunization programs, supported by international health organizations and governments, has increased the demand for vaccines, especially in underdeveloped and developing regions. Additionally, consumer behavior has shifted significantly in recent years, with a growing preference for preventive healthcare measures, further spurred by the COVID-19 pandemic’s demonstration of the critical role of vaccinations in controlling infectious diseases. The market's expansion is also facilitated by the rise in travel and migration, which increases the exposure to different pathogens, thereby boosting the need for broader immunization coverage. This dynamic market is expected to continue growing as new vaccine technologies and international health initiatives expand to meet the challenges of existing and emerging infectious diseases.

Select Competitors (Total 86 Featured) -

  • AstraZeneca PLC
  • Bharat Biotech International Ltd.
  • Boehringer Ingelheim International GmbH
  • Daiichi Sankyo Co., Ltd.
  • Emergent BioSolutions, Inc.
  • GSK Plc
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novavax, Inc.
  • Pfizer, Inc.
  • Roche CustomBiotech
  • Sanofi SA
  • Serum Institute of India Pvt., Ltd.
  • Takeda Pharmaceutical Co., Ltd.;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Preventable Vaccines - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Preventable Diseases
    • Increasing Government Immunization Programs
    • Advances in Vaccine Development Technologies
    • Growing Awareness of Vaccine Importance
    • Expansion of Global Vaccination Initiatives
    • Development of Combination Vaccines
    • Increasing Investment in Vaccine R&D
    • Technological Innovations in Vaccine Delivery Systems
    • Growth of Adult and Travel Vaccination Programs
    • Public Health Campaigns and Education Efforts
    • Adoption of Novel Vaccine Platforms (e.g., mRNA, viral vectors)
    • Rising Demand for Pediatric Vaccinations
    • Vaccine Hesitancy and Public Trust Issues
    • Expansion of Vaccine Manufacturing Capabilities
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Preventable Vaccines Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Preventable Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Preventable Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Preventable Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Live / Attenuated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Live / Attenuated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Live / Attenuated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Inactivated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Inactivated Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Inactivated Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Subunit Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Subunit Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Subunit Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Toxoid Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Toxoid Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Toxoid Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Vaccine Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Vaccine Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Vaccine Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Measles & Rubella Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Measles & Rubella Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Measles & Rubella Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Poliovirus Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Poliovirus Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Poliovirus Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Pneumococcal Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Pneumococcal Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: World 16-Year Perspective for Pneumococcal Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Hepatitis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Hepatitis Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: World 16-Year Perspective for Hepatitis Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Influenza Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Influenza Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: World 16-Year Perspective for Influenza Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Public Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Public Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: World 16-Year Perspective for Public Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Private Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Private Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: World 16-Year Perspective for Private Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Preventable Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 44: USA Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: USA 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: USA 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: USA 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Canada 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Canada 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Canada 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • JAPAN
    • Preventable Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Japan 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Japan 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Japan 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • CHINA
    • Preventable Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 71: China Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: China 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: China 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: China 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • EUROPE
    • Preventable Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Preventable Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Preventable Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Europe 16-Year Perspective for Preventable Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Europe 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Europe 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • FRANCE
    • Preventable Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 92: France Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: France 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: France 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: France 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • GERMANY
    • Preventable Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Germany 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Germany 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Germany 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Italy 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Italy 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Italy 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Preventable Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 119: UK Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: UK 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: UK 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: UK 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Spain 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Spain 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 134: Spain Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Spain Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Spain 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Russia 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Russia 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 143: Russia Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Russia Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Russia 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Rest of Europe 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Rest of Europe 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Rest of Europe 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Preventable Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Preventable Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Preventable Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Asia-Pacific 16-Year Perspective for Preventable Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Asia-Pacific 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Asia-Pacific 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Asia-Pacific 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Preventable Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Australia 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Australia 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 173: Australia Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Australia Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Australia 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • INDIA
    • Preventable Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 176: India Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: India 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: India 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 182: India Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: India Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: India 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: South Korea 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: South Korea 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 191: South Korea Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: South Korea Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: South Korea 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Asia-Pacific Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Asia-Pacific 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Preventable Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Preventable Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Preventable Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Latin America 16-Year Perspective for Preventable Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Latin America 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Latin America 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Latin America Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Latin America 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 217: Argentina 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 220: Argentina 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 221: Argentina Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 222: Argentina Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 223: Argentina 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 226: Brazil 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 229: Brazil 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 230: Brazil Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 231: Brazil Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 232: Brazil 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 235: Mexico 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 238: Mexico 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 239: Mexico Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 240: Mexico Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 241: Mexico 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 244: Rest of Latin America 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 247: Rest of Latin America 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 249: Rest of Latin America Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 250: Rest of Latin America 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Preventable Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Preventable Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Preventable Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 253: Middle East 16-Year Perspective for Preventable Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 256: Middle East 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 259: Middle East 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 261: Middle East Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 262: Middle East 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 265: Iran 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 268: Iran 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 269: Iran Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 270: Iran Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 271: Iran 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 274: Israel 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 277: Israel 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 278: Israel Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 279: Israel Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 280: Israel 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 283: Saudi Arabia 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 286: Saudi Arabia 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 288: Saudi Arabia Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 289: Saudi Arabia 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 292: UAE 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 295: UAE 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 296: UAE Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 297: UAE Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 298: UAE 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 301: Rest of Middle East 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 304: Rest of Middle East 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 306: Rest of Middle East Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 307: Rest of Middle East 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030
  • AFRICA
    • Preventable Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Preventable Vaccines by Vaccine Type - Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 310: Africa 16-Year Perspective for Preventable Vaccines by Vaccine Type - Percentage Breakdown of Value Sales for Live / Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Toxoid Vaccines and Other Vaccine Types for the Years 2014, 2024 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Preventable Vaccines by Disease Type - Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 313: Africa 16-Year Perspective for Preventable Vaccines by Disease Type - Percentage Breakdown of Value Sales for Measles & Rubella Disease, Other Disease Types, Poliovirus Disease, Pneumococcal Disease, Hepatitis Disease and Influenza Disease for the Years 2014, 2024 & 2030
    • TABLE 314: Africa Recent Past, Current & Future Analysis for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 315: Africa Historic Review for Preventable Vaccines by Distribution Channel - Public Distribution Channel and Private Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 316: Africa 16-Year Perspective for Preventable Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Public Distribution Channel and Private Distribution Channel for the Years 2014, 2024 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제